BIOTECHNOLOGY - V. H. Gerasymenko - 2006

Part II. Specialized Biotechnologies

Chapter 14. BIOTECHNOLOGY OF MONOCLONAL ANTIBODY PRODUCTION (SINGLE-EPITOPE ANTIBODIES)

14.3. APPLICATIONS OF MONOCLONAL ANTIBODIES

First and foremost, they are used in veterinary medicine to develop diagnostic kits for viral infections. Hybridomas capable of biosynthesizing Monoclonal Antibodies against epitopes of the Venezuelan equine encephalomyelitis virus, African swine fever virus, bovine respiratory syncytial virus, leukemia, rabies, vesicular stomatitis, Influenza, parainfluenza-3, and other diseases have already been successfully obtained. Replacing traditional polyclonal antibodies with monoclonal ones in standard Diagnostics has led to the creation of a new generation of diagnostic products. Their advantages include high Specificity and sensitivity, which ensure the identification not only of the pathogen species but also of its serotype. They can be standardized, and The production of diagnostics is more cost-effective. The Use of monoclonal antibodies has significantly enhanced the efficiency of such diagnostic assays as enzyme-linked immunosorbent assay (ELISA), passive hemagglutination, and immunofluorescence.

Monoclonal antibodies are also utilized for passive immunization against certain viral diseases (such as rabies and tick-borne encephalitis).

Immobilized monoclonal antibodies serve as immunosorbents, ensuring continuous Processing in the purification of Insulin, interferon, somatotropic hormone, and other BIOLOGICALLY ACTIVE SUBSTANCES whose Biosynthesis relies on Recombinant DNA technology. Furthermore, monoclonal antibodies provide an effective means to verify the identity of industrially produced biotechnological Proteins AND Peptides against samples from natural sources.

Fluorescently labeled monoclonal antibodies directed against antigenic determinants of sperm Membrane Proteins can be used for sex-sorting spermatozoa to address practical breeding challenges.

Monoclonal antibodies enable the targeted delivery of therapeutic agents to Cells carrying the corresponding epitope. This approach enhances the efficacy of drugs against infectious diseases and Cancer. By utilizing monoclonal antibodies derived from animals immunized with specific pharmaceutical drugs, it is also possible to determine the appropriate dosage of these medications.

In autoimmune disorders—where immune cells mistakenly attack the body's own Organs and Tissues—monoclonal antibodies of appropriate specificity can bind and neutralize the pathogenic antibodies. For cancer therapy, researchers propose using monoclonal antibodies conjugated with compounds toxic to cancer cells. Monoclonal antibodies deliver the toxin precisely to the target site, sparing healthy cells from damage. Consequently, highly potent toxins can be safely coupled with monoclonal antibodies.

Monoclonal antibodies are of great interest for The Development of anti-idiotypic Vaccines, which represent a novel Class of immunizing agents. In 1963, H. Kunkel and colleagues (USA) and J. Oudin (France), working independently, discovered that antibodies obtained through animal immunization (Ab-1), when isolated from serum and injected into other animals, induced the synthesis of new antibodies—Ab-2. These latter antibodies (Ab-2) specifically bound only to Ab-1 and did not cross-react with other antibodies. This led J. Oudin to term the epitope of the Ab-1 antibody an "idiotype" (from the Greek idios meaning peculiar and typos meaning imprint, model, or form), while the Ab-2 antibody, generated in response to the antigenic determinants of the idiotype (Ab-1), was termed the "anti-idiotype." Subsequent experiments demonstrated a structural similarity between Ab-2 and the original antigen. This gave rise to METABOLISM/2.html">THE CONCEPT OF using Ab-2 as a vaccine with distinct advantages. The primary advantage is that while maintaining high specificity, anti-idiotypic vaccines can never induce the actual disease they are designed to protect against.

This method holds great promise for working with hazardous Viruses, as well as those whose production is limited or associated with significant technical difficulties. It is also promising when antigenic determinants include CARBOHYDRATES or Lipids that hinder the development of vaccines via Introduction/32.html">Genetic Engineering principles.

The application of appropriate anti-idiotypes is highly effective for the Prevention of numerous infectious diseases, the Treatment of certain types of cancer, and the management of immune system disorders. Anti-idiotypes can be employed as vaccines or therapeutic agents to combat Acquired Immunodeficiency Syndrome (AIDS).